Theriva Biologics Inc. announced that it was unable to convene its Special Meeting of Stockholders on February 11, 2026, due to a lack of quorum. The meeting was intended to seek shareholder approval for the issuance of up to 16,184,560 shares of common stock upon the exercise of common stock purchase warrants issued under a warrant inducement agreement with certain institutional investors. The company will reschedule the meeting and continue to call additional meetings every 60 days, as required by the agreement, until the necessary approval is obtained or the warrants are no longer outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-013907), on February 12, 2026, and is solely responsible for the information contained therein.